Clinical Trial Update: A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007) [Phase 1]

View source ↗

Summary

Phase 1 trial update on MK-8189 assessing safety, tolerability, and pharmacokinetics in participants with schizophrenia and healthy volunteers; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• MK-8189

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2021-03-29